Moxidectin: heartworm disease prevention in dogs in the face of emerging macrocyclic lactone resistance

Parasites & Vectors

Table 2 Preventive efficacy of orally administered moxidectin against macrocyclic lactone-resistant heartworm strains utilizing various dosages and dosage regimens [48]

Study	Strain^a	Treatment^b	Dosage (µg/kg)	Days of treatment	Preventive efficacy (%)
1	JYD-34	Placebo	0	0, 30, 60	–
	JYD-34	Moxidectin	3	0	19
	JYD-34	Moxidectin	3	0, 30, 60	44.4
	JYD-34	Moxidectin	6	0	25.5
	JYD-34	Moxidectin	12	0	33.3
	JYD-34	Moxidectin	24	0	53.2
2	JYD-34	Placebo	0	0, 28, 56	–
	JYD-34	Moxidectin	24	0, 28, 56	98.8
	JYD-34	Moxidectin	40	0, 28, 56	100
	JYD-34	Moxidectin	60	0, 28, 56	100
	ZoeLA	Placebo	0	0, 28, 56	–
	ZoeLA	Moxidectin	3	0	44.4
	ZoeLA	Moxidectin	24	0, 28, 56	99.5
	ZoeLA	Moxidectin	40	0, 28, 56	99.5
	ZoeLA	Moxidectin	60	0	88.2
	ZoeLA	Moxidectin	60	0, 28, 56	100
3	ZoeMO	Placebo	0	0, 28, 56	–
	ZoeMO	Moxidectin	3	0	82.1
	ZoeMO	Moxidectin	24	0, 28, 56	99.5
	ZoeMO	Moxidectin	40	0, 28, 56	100
	ZoeMO	Moxidectin	60	0, 28, 56	100

^aEach dog inoculated with 50 third-stage larvae of the specific strain ~ 1 month prior to the first treatment
^bFor each treatment group, n = 5

ISSN: 1756-3305